For instance, while KRAS mutation is very frequent in CRC (about 40% of the cases), it is much less frequent in breast cancer and, in particular, in ER positive breast cancers (less than 1%), the tumor subtype in which CDK4/6i are more active [47]. This evidence concerns the gene KRAS and neoplasm.